Ginkgo biloba and its Influence on Nanoplaque Formation and Vascular Function

• Background: In a pilot study, we demonstrated the beneficial effects of Ginkgo biloba (EGb 761) on atherosclerotic nanoplaque formation and size, the oxLDL/LDL quotient and the lipoprotein(a) concentration, the increase in superoxide dismutase activity, as well as the cAMP and cGMP concentrations. Method: The measurable variables formerly used were supplemented by a biomarker spectrum, through which the latest parameter and markers of plaque stability and progression, oxidative stress, and inflammation could be determined. Results: In 11 patients with early-stage metabolic syndrome, atherosclerotic nanoplaque formation fell by 14.3 +/- 2.9 (p < 0.0077) and nanoplaque size by 23.4 +/- 3.7 % (p < 0.0004), respectively, after a two-month regime with Ginkgo biloba extract. Superoxide dismutase and glutathione peroxidase (GPx) activities were upregulated by 19.6 +/- 10.0 % (p < 0.0785) and 11.6 +/- 2.3 % (p < 0.001), respectively. The quotient oxLDL/LDL fell by 21.0 +/- 4.3 % (p < 0.002), and lipoprotein(a) concentration by 26.3 t 4.8 % (p < 0.001). The concentrations of cAMP and cGMP were augmented by43.5 12.0% (p < 0.001)and 32.9 +/- 10.4% (p < 0.001), respectively. The serum Call concentration fell by 5.4 +/- 1.6 % (p < 0.0076). We could also show a favourable development of 8-iso-PGF(2 alpha), oxLDL/LDL, SOD, GPx, hsCRP MPO,TNF alpha, TGF beta(1), and MMP-9. Conclusion: Ginkgo with its pleiotropic effects should be assigned a fixed rank among the anti-ageing medical therapeutics.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)

Nyckelord

metabolic syndrome

Ginkgo biloba

nanoplaque formation

nanoplaque size

PHARMACY

FARMACI

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)